Operable Breast Cancer: Neoadjuvant Treatment (Methodology)

  • Manfred Kaufmann
  • Sibylle Loibl
  • Gunter von Minckwitz
Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT, volume 1)

Primary operable breast cancer has been treated by neoadjuvant systemic therapy (NST) to make breast conservation possible in some patients with operable disease who otherwise would require a mastectomy. Nowadays, the surgical defect is expected to be as limited as possible. Neoadjuvant systemic therapy has become widely accepted as the treatment of choice for patients with locally advanced disease, large inoperable tumors or inflammatory disease to convert inoperable to operable primary tumors. Although the terms primary systemic therapy and preoperative therapy are more accurate descriptions of this treatment, NST is the term that has come into broad use, and that is the term we will use here (Kaufmann et al., 2003, 2006).

Keywords

Oncol Paclitaxel Doxorubicin Tamoxifen Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrial, S.C., Penault-Llorca, F., Delva, R., Bougnoux, P., Leduc, B., Mouret-Reynier, M.A., Mery-Mignard, D., Bleuse, J.P., Dauplat, J., Cure, H., and Chollet, P. 2005. High prognostic significance of residual disease after neoad-juvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res. Treat. 94: 255–263PubMedCrossRefGoogle Scholar
  2. Bozzetti, C., Musolino, A., Camisa, R., Bisagni, G., Flora, M., Bassano, C., Martella, E., Lagrasta, C., Nizzoli, R., Personeni, N., Leonardi, F., Cocconi, G., and Ardizzoni, A. 2006. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. Am. J. Clin. Oncol. 29: 171–177PubMedCrossRefGoogle Scholar
  3. Burcombe, R.J., Makris, A., Richman, P.I., Daley, F.M., Noble, S., Pittam, M., Wright, D., Allen, A., Dove, J., and Wilson, G.D. 2005. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neo-adjuvant anthracycline chemotherapy for operable breast cancer. Br. J. Cancer 92: 147–155PubMedCrossRefGoogle Scholar
  4. Buzdar, A.U., Valero, V. , Ibrahim, N. K., Francis, D., Broglio, K. R., Theriault, R. L., Pusztai, L., Green, M. C., Singletary, S. E., Hunt, K. K., Sahin, A. A., Esteva, F., Symmans, W. F , Ewer, M. S., Buchholz, T. A., and Hortobagyi, G.N. 2007. Neoadjuvant therapy with paclit-axel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin. Cancer Res. 13: 228–233PubMedCrossRefGoogle Scholar
  5. Cameron, D.A., Anderson, E.D., Levack, P., Hawkins, R.A., Anderson, T.J., Leonard, R.C., Forrest, A.P., and Chetty, U. 1997. Primary systemic therapy for operable breast cancer — 10-year survival data after chemotherapy and hormone therapy. Br. J. Cancer 76: 1099–1105PubMedGoogle Scholar
  6. Chagpar, A.B., Middleton, L.P., Sahin, A.A., Dempsey, P., Buzdar, A.U., Mirza, A.N., Ames, F.C., Babiera, G.V., Feig, B.W., Hunt, K.K., Kuerer, H.M., Meric-Bernstam, F., Ross, M.I., and Singletary, S.E. 2006. Accuracy of physical examination, ultrasonography, and mammog-raphy in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann. Surg. 243: 257–264PubMedCrossRefGoogle Scholar
  7. Chen, A.M., Meric-Bernstam, F., Hunt, K.K., Thames, H.D., Outlaw, E.D., Strom, E.A., McNeese, M.D., Kuerer, H.M., Ross, M.I., Singletary, S.E., Ames, F.C., Feig, B.W., Sahin, A.A., Perkins, G.H., Babiera, G., Hortobagyi, G.N., and Buchholz, T.A. 2005. Breast conservation after neoadjuvant chemotherapy.Cancer 103: 689–695PubMedCrossRefGoogle Scholar
  8. Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., Godwin, J., Gray, R., Hicks, C., James, S., MacKinnon, E., McGale, P., McHugh, T., Peto, R, Taylor, C., and Wang, Y. 2005. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366: 2087–2106PubMedGoogle Scholar
  9. Colleoni, M., Viale, G., Zahrieh, D., Pruneri, G., Gentilini, O., Veronesi, P., Gelber, R.D., Curigliano, G., Torrisi, R., Luini, A., Intra, M., Galimberti, V. , Renne, G., Nole, F., Peruzzotti, G., and Goldhirsch, A. 2004. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 10: 6622–6628PubMedCrossRefGoogle Scholar
  10. Davidson, N.E., and Morrow, M. 2005. Sometimes a great notion—an assessment of neoadjuvant systemic therapy for breast cancer. J. Natl. Cancer Inst. 97: 159–161PubMedCrossRefGoogle Scholar
  11. Del Mastro, L., Catzeddu, T., Boni, L., Bell, C., Sertoli, M.R., Bighin, C., Clavarezza, M., Testa, D., and Venturini, M. 2006. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann. Oncol. 17: 74–78PubMedCrossRefGoogle Scholar
  12. Della Pasqua, S., Balduzzi, A., and Torrisi, R. 2006. Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. J. Clin. Oncol. 24: suppl abstrGoogle Scholar
  13. Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin, J., Vinholes, J., Mauriac, L., Ellis, M., Lassus, M., Chaudri-Ross, H.A., Dugan, M., and Borgs, M. 2001. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann. Oncol. 12: 1527–1532PubMedCrossRefGoogle Scholar
  14. Esserman, L., Hylton, N., Yassa, L., Barclay, J., Frankel, S., and Sickles, E. 1999. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preopera-tive staging. J. Clin. Oncol. 17: 110–119PubMedGoogle Scholar
  15. Evans, T.R., Yellowlees, A., Foster, E., Earl, H., Cameron, D.A., Hutcheon, A.W., Coleman, R.E., Perren, T., Gallagher, C.J., Quigley, M., Crown, J., Jones, A.L., Highley, M., Leonard, R. C., and Mansi, J.L. 2005. Phase III randomized trial of doxorubicin and docetaxel versus doxo-rubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J. Clin. Oncol. 23: 2988–2995PubMedCrossRefGoogle Scholar
  16. Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E.R., Wickerham, D.L., Begovic, M., DeCillis, A., Robidoux, A., Margolese, R.G., Cruz, A.B., Jr., Hoehn, J.L, Lees, A.W., Dimitrov, N.V., and Bear, H.D. 1998. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16: 2672–2685PubMedGoogle Scholar
  17. Garg, A.K., Strom, E.A., McNeese, M.D., Buzdar, A.U., Hortobagyi, G.N., Kuerer, H.M., Perkins, G.H., Singletary, S.E., Hunt, K.K., Sahin, A., Schechter, N., Valero, V., Tucker, S.L., and Buchholz, T.A. 2004. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadju-vant chemotherapy and mastectomy without radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59: 138–145PubMedGoogle Scholar
  18. Green, M.C., Buzdar, A.U., Smith, T., Ibrahim, N.K., Valero, V., Rosales, M.F., Cristofanilli, M., Booser, D.J., Pusztai, L., Rivera, E., Theriault, R.L., Carter, C., Frye, D., Hunt, K.K., Symmans, W.F., Strom, E.A., Sahin, A.A., Sikov, W., and Hortobagyi, G.N. 2005. Weekly paclit-axel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J. Clin. Oncol. 23: 5983–5992PubMedCrossRefGoogle Scholar
  19. Hennessy, B.T., Hortobagyi, G.N., Rouzier, R., Kuerer, H., Sneige, N., Buzdar, A.U., Kau, S.W., Fornage, B., Sahin, A, Broglio, K., Singletary, S.E., and Valero, V. 2005. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J. Clin. Oncol. 23: 9304–9311PubMedCrossRefGoogle Scholar
  20. Huang, E.H., Tucker, S.L., Strom, E.A., McNeese, M. D., Kuerer, H.M., Buzdar, A.U., Valero, V., Perkins, G.H., Schechter, N.R., Hunt, K.K., Sahin, A.A., Hortobagyi, G.N., and Buchholz, T.A. 2004. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J. Clin. Oncol. 22: 4691–4699PubMedCrossRefGoogle Scholar
  21. Jones, R.L., Lakhani, S.R., Ring, A.E., Ashley, S., Walsh, G., and Smith, I.E. 2006. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br. J. Cancer 94: 358–362PubMedCrossRefGoogle Scholar
  22. Kaufmann, M., von Minckwitz G., Smith, R., Valero, V., Gianni, L., Eiermann, W., Howell, A., Costa, S. D., Beuzeboc, P., Untch, M., Blohmer, J.U., Sinn, H.P., Sittek, R., Souchon, R., Tulusan, A.H., Volm, T., and Senn, H.J. 2003. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer:review and recommendations. J. Clin. Oncol. 21: 2600–2608PubMedCrossRefGoogle Scholar
  23. Kaufmann, M., Hortobagyi, G.N., Goldhirsch, A., Scholl, S., Makris, A., Valagussa, P., Blohmer, J.U., Eiermann, W., Jackesz, R., Jonat, W., Lebeau, A., Loibl, S., Miller, W., Seeber, S., Semiglazov, V. , Smith, R., Souchon, R., Stearns, V. , Untch, M., and von Minckwitz G. 2006. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 24: 1940–1949PubMedCrossRefGoogle Scholar
  24. Kim, T., Giuliano, A.E., and Lyman, G.H. 2006. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaa-nalysis. Cancer 106: 4–16PubMedCrossRefGoogle Scholar
  25. Klauber-DeMore, N., Ollila, D.W., Moore, D.T., Livasy, C., Calvo, B.F., Kim, H.J., Dees, E.C., Sartor, C.I., Sawyer, L.R., Graham, M., and Carey, L.A. 2006. Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic. Ann. Surg. Oncol. 13: 685–691PubMedCrossRefGoogle Scholar
  26. Kuehn, T., Bembenek, A., Decker, T., Munz, D.L., Sautter-Bihl, M.L., Untch, M., and Wallwiener, D. 2005. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer 103: 451–461PubMedCrossRefGoogle Scholar
  27. Loibl, S., Blohmer, J.-U., and Raab, G. 2005. Prospective central assessment of HER-2 status by FISH is not a predictive factor for pathologic complete response (pCR) in 648 breast cancer patients treated preoperatively with an anthracycline/tax-ane based regimen in the multicenter GeparTrio trial. Breast Cancer Res. Treat. 94: 46 abstrGoogle Scholar
  28. Loibl, S., von Minckwitz G., Raab, G., Blohmer, J.-U., Dan Costa, S., Gerber, B., Eidtmann, H., Petrich, S., Hilfrich, J., Jackisch, C., du Bois, A., and Kaufmann, M. 2006. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann. Surg. Oncol. 13: 1434–1442PubMedCrossRefGoogle Scholar
  29. MacGrogan, G., Rudolph, P., Mascarel, Id.I, Mauriac, L., Durand, M., Avril, A., Dilhuydy, J.M., Robert, J., Mathoulin-Pelissier, S., Picot, V. , Floquet, A., Sierankowski, G., and Coindre, J.M. 2003. DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer. Br. J. Cancer 89: 666–671PubMedCrossRefGoogle Scholar
  30. Mamounas, E.P., Brown, A., Anderson, S., Smith, R., Julian, T., Miller, B., Bear, H.D., Caldwell, C.B., Walker, A.P., Mikkelson, W.M., Stauffer, J.S., Robidoux, A., Theoret, H., Soran, A., Fisher, B., Wickerham, D.L., and Wolmark, N. 2005. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 23: 2694–2702PubMedCrossRefGoogle Scholar
  31. Manton, D. J., Chaturvedi, A., Hubbard, A., Lind, M. J., Lowry, M., Maraveyas, A., Pickles, M.D., Tozer, D.J., and Turnbull, L.W. 2006. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br. J. Cancer 94: 427–435PubMedCrossRefGoogle Scholar
  32. Mardor, Y., Pfeffer, R., Spiegelmann, R., Roth, Y. , Maier, S.E., Nissim, O., Berger, R., Glicksman, A., Baram, J., Orenstein, A., Cohen, J.S., and Tichler, T. 2003. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J. Clin. Oncol. 21: 1094–1100PubMedCrossRefGoogle Scholar
  33. Mauri, D., Pavlidis, N., and Ioannidis, J.P. 2005. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J. Natl. Cancer Inst. 97: 188–194PubMedCrossRefGoogle Scholar
  34. Mustacchi, G., Ceccherini, R., Milani, S., Pluchinotta, A., De Matteis, A, Maiorino, L., Farris, A., Scanni, A., and Sasso, F.. 2003. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann. Oncol. 14: 414–420PubMedCrossRefGoogle Scholar
  35. Peintinger, F., Kuerer, H.M., Anderson, K., Boughey, J.C., Meric-Bernstam, F., Singletary, S.E., Hunt, K.K., Whitman, G.J., Stephens, T., Buzdar, A.U., Green, M.C., and Symmans, W.F. 2006. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann. Surg. Oncol. 13: 1443–1449PubMedCrossRefGoogle Scholar
  36. Ring, A., Webb, A., Ashley, S., Allum, W.H., Ebbs, S., Gui, G., Sacks, N.P., Walsh, G., and Smith, I.E. 2003. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J. Clin. Oncol. 21: 4540–4545PubMedCrossRefGoogle Scholar
  37. Ring, A.E., Smith, I.E., Ashley, S., Fulford, L.G., and Lakhani, S.R. 2004. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer 91: 2012–2017PubMedCrossRefGoogle Scholar
  38. Rody, A., Karn, T., Gatje, R., Ahr, A., Solbach, C., Kourtis, K., Munnes, M., Loibl, S, Kissler, S, Ruckhaberle, E., Holtrich, U., von Minckwitz G., and Kaufmann, M. 2007. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associ-ated protein tau, is highly predictive of tumor response. Breast 16: 86–93PubMedCrossRefGoogle Scholar
  39. Sadetzki, S., Oberman, B., Zipple, D., Kaufman, B., Rizel, S., Novikov, I., and Papa, M.Z. 2005. Breast conservation after neoadjuvant chemotherapy. Ann. Surg. Oncol. 12: 480–487PubMedCrossRefGoogle Scholar
  40. Scholl, S. M., Fourquet, A., Asselain, B., Pierga, J. Y. , Vilcoq, J.R., Durand, J.C., Dorval, T., Palangie, T., Jouve, M., Beuzeboc, P. 1994. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur. J. Cancer 30A: 645–652PubMedCrossRefGoogle Scholar
  41. Senofsky, G.M., Gierson, E.D., Craig, P.H., Gamagami, P.P., and Silverstein, M.J. 1998. 1998. Local excision, lumpectomy, and quadran-tectomy. Surgical considerations. Surgery of the Breast: Principles and Art. Lippincott-Raven, Philadelphia, pp. 129–135Google Scholar
  42. Smith, I.C., Heys, S.D., Hutcheon, A.W., I. D. Miller, I.D., Payne, S., Gilbert, F.J., Ah-See, A.K., Eremin, O., Walker, L.G., Sarkar, T.K., Eggleton, S.P., and Ogston, K.N. 2002. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. Oncol. 20: 1456–1466PubMedCrossRefGoogle Scholar
  43. Smith, I.E., Dowsett, M., Ebbs, S.R., Dixon, J. M., Skene, A., Blohmer, J.U., Ashley, S.E. Francis, S., Boeddinghaus, I., and Walsh, G. 2005. Neoadjuvant treatment of postmenopau-sal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multi-center double-blind randomized trial. J. Clin. Oncol. 23: 5108–5116PubMedCrossRefGoogle Scholar
  44. Taghian, A.G., bi-Raad, R., Assaad, S.I., Casty, A., Ancukiewicz, M., Yeh, E., Molokhia, P., Attia, K., Sullivan, T., Kuter, I., Boucher, Y., and Powell, S.N. 2005. Paclitaxel decreases the interstitial fluid pressure and improves oxygena-tion in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J. Clin. Oncol. 23: 1951–1961PubMedCrossRefGoogle Scholar
  45. Thomas, E., Holmes, F.A., Smith, T.L., Buzdar, A.U., Frye, D.K., Fraschini, G., Singletary, S.E., Theriault, R.L., McNeese, M.D., Ames, F., Walters, R., and Hortobagyi, G.N. 2004. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J. Clin. Oncol. 22: 2294–2302PubMedCrossRefGoogle Scholar
  46. Torrisi, R., Colleoni, M., Veronesi, P., Rocca, A., Peruzzotti, G., Severi, G., Medici, M., Renne, G., Intra, M., Luini, A., Nole, F., Viale, G., and Goldhirsch, A. 2007. Primary therapy with ECF in combination with a GnRH analog in premeno-pausal women with hormone receptor-positive T2-T4 breast cancer. Breast 16: 73–80PubMedCrossRefGoogle Scholar
  47. von Minckwitz, G., Costa, S.D., Raab, G., Blohmer, J.U., Eidtmann, H., Hilfrich, J., Merkle, E., Jackisch, C., Gademann, G., Tulusan, A.H., Eiermann, W., Graf, E., and Kaufmann, M. 2001. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J. Clin. Oncol. 19: 3506–3515Google Scholar
  48. von Minckwitz, G., Raab, G., Caputo, A., Schutte, M., Hilfrich, J., Blohmer, J.U., Gerber, B., Costa, S.D., Merkle, E., Eidtmann, H., Lampe, D., Jackisch, C., du Bois, A., and Kaufmann, M. 2005. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J. Clin. Oncol. 23: 2676–2685CrossRefGoogle Scholar
  49. Wasser, K., Klein, S.K., Fink, C., Junkermann, H., Sinn, H.P., Zuna, I., Knopp, M.V., and Delorme, S. 2003. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur. Radiol. 13: 80–87PubMedGoogle Scholar
  50. Wenzel, C., Bartsch, R., Hussian, D., Pluschnig, U., Altorjai, G., Zielinski, C.C., Lang, A., Haid, A., Jakesz, R., Gnant, M., and Steger, G.G. 2007. Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res. Treat. published online: 24 October 2006Google Scholar
  51. Xing, Y. , Foy, M., Cox, D.D., Kuerer, H.M., Hunt, K.K., and Cormier, J.N. 2006. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br. J. Surg. 93: 539–546PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2008

Authors and Affiliations

  • Manfred Kaufmann
    • 1
  • Sibylle Loibl
    • 2
  • Gunter von Minckwitz
    • 2
  1. 1.Department of Obstetrics and GynecologyJ.W. Goethe University HospitalFrankfurtGermany
  2. 2.Department of Obstetrics and GynecologyGerman Breast GroupNeu-IsenburgGermany

Personalised recommendations